Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $32.72 Analyst target: $60.00 Upside: 83.37%
UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel technology, the company enables targeted, sustained drug delivery, maximizing treatment efficacy while reducing systemic side effects. UroGen's strong clinical pipeline underscores its commitment to addressing substantial unmet medical needs in the oncology space, positioning the company as a potential leader in the urological oncology market and significantly improving patient outcomes.
See the full interactive analysis & chart →Informational only — not investment advice.